The deal – terms of which were not disclosed – will grant Carbogen access to Austria-based Polymun’s liposomal formulation technology for use in the formulations of active pharmaceutical ingredients (APIs).
In return Polymun will be able to use Carbogen’s development and manufacturing capabilities.
Carbogen CEO Mark Griffiths set out the rationale for the agreement, explaining that: “We believe that our customers are interested in finding new ways to better deliver highly potent active ingredients. This alliance expands our portfolio of offering and moves us one step closer to achieving this goal.”
The Switzerland-based API maker has been expanding its high-potency API manufacturing business since February this year under a restructuring plan launched by Indian parent organisation Dishman in response to ‘inadequate profitability’ at the Swiss CMO.
Under that plan the active pharmaceutical ingredient (API) chose to focus operations at its Aarau, Switzerland on development projects and shift pilot production for early-stage compounds to its facility in Huzenschwil.
Large volume production for standard APIs and highly active agents continued at Carbogen's facility in Bubendorf.
There was more news for Carbogen’s HPAPI business this month process after the firm successfully completed a US Food and Drug Administration (FDA) pre-approval inspection for the manufacture of a HP API on behalf of an unnamed multinational pharmaceutical organisation.
Carbogen was unable to provide further information on the specifics of the agreement ahead of publication.